Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06529406 · ClinicalTrials.gov registry record · Phase 4
Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod
A Phase 4 study of Relapsing Multiple Sclerosis, sponsored by University of Colorado, Denver.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
- 3
- Study locations
NCT06529406: Recruiting Phase 4 study of Relapsing Multiple Sclerosis, sponsored by University of Colorado, Denver.
NCT06529406 is a Phase 4 study of Relapsing Multiple Sclerosis that is actively recruiting participants, run by University of Colorado, Denver. The registered enrollment target is 100 participants, below the 2,165-participant average among 23 other Relapsing Multiple Sclerosis trials with a reported enrollment target (95% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06529406, a Phase 4 study of Relapsing Multiple Sclerosis, is actively recruiting participants, sponsored by University of Colorado, Denver.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
- 3
- Study locations
Study Summary
A multi-center pilot study to evaluate safety and efficacy of ozanimod as de-escalation therapy in clinically stable MS patients previously treated with anti-CD20 therapy.
Primary Outcome
Number of new T2 lesions on MRI scans.
Conditions Studied
Interventions
- DRUG Ozanimod
Study Locations (3)
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
Nevada
- Cleveland Clinic - Las Vegas
Ohio
- Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2024-07-29 |
| Est. Completion | 2029-08-01 |
| Phase | Phase 4 |
What NCT06529406 shows while recruiting
NCT06529406 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 2,165-participant average among 23 other Relapsing Multiple Sclerosis trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Relapsing Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which Ozanimod is the first listed.
NCT06529406 reports a single indexed study location in Colorado, Nevada, Ohio.
Frequently Asked Questions
What is clinical trial NCT06529406 about?
NCT06529406 is a clinical study titled "Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod". A multi-center pilot study to evaluate safety and efficacy of ozanimod as de-escalation therapy in clinically stable MS patients previously treated with anti-CD20 therapy.
What is the current status of trial NCT06529406?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2024-07-29. Estimated completion is 2029-08-01.
What conditions does trial NCT06529406 study?
This clinical trial studies the following conditions: Relapsing Multiple Sclerosis.
What interventions are being tested in trial NCT06529406?
The interventions under investigation include: Ozanimod (DRUG).
Who is sponsoring clinical trial NCT06529406?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06529406 being conducted?
This trial has 3 study locations across Colorado, Nevada, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsing Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06529406's enrollment target sits among peer trials
100 20th of 23 higher than 4 of 23 other Relapsing Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Relapsing Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset
ACTIVE NOT RECRUITING · Phase 4
-
Effects of Ocrevus in Relapsing Multiple Sclerosis
ACTIVE NOT RECRUITING · Phase 4
-
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
RECRUITING · Phase 3
-
Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis
RECRUITING · Phase 3
-
A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk
RECRUITING
-
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI